Comparative effectiveness of Low-Molecular-Weight Heparins versus other anticoagulants in major orthopedic surgery: A systematic review and meta-analysis

Pharmacotherapy

Volumn 32, Issue 9, 2012, Pages 799-808

  Sobieraj, Diana M ^a   Coleman, Craig I ^a   Tongbram, Vanita ^a   Chen, Wendy ^a   Colby, Jennifer ^a   Lee, Soyon ^a   Kluger, Jeffrey ^a   Makanji, Sagar ^a   Ashaye, Ajibade ^a   White, C Michael ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

Anticoagulant prophylaxis; Hip fracture surgery; Orthopedic surgery; Total hip replacement; Total knee replacement; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A INHIBITOR; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; THROMBIN INHIBITOR;

BLEEDING; COMPARATIVE EFFECTIVENESS; DEEP VEIN THROMBOSIS; DRUG SAFETY; EMBOLISM PREVENTION; FRACTURE TREATMENT; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LUNG EMBOLISM; META ANALYSIS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; HEMORRHAGE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HIP FRACTURES; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBOEMBOLISM; VITAMIN K;

EID: 84867585437     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1875-9114.2012.01106.x     Document Type: Review

References (45)

1. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008;133:381S-453S.
2. American Academy of Orthopaedic Surgeons. Clinical guideline on prevention of pulmonary embolism in patients undergoing total hip or knee arthroplasty. Available from Http:// www.aaos.org/research/guidelines/Peguide. asp. Accessed January 27, 2010.
3. Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). The PIOPED Investigators. JAMA 1990;263:2753-2759.
4. Biello DR, Mattar AG, McKnight RC, et al. Ventilation-perfusion studies in suspected pulmonary embolism. AJR 1979;133:1033-1037.
5. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. AHRQ Publication No. 10(11)-EHC063-EF. Rockville, MD: Agency for Healthcare Research and Quality; Available from www.effectivehealthcare.ahrq.gov. Accessed January 1, 2011.
6. Bradburn MJ, Deeks JJ, Berlin JA, et al. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 2007;26:53-77.
7. Higgins JPT, Green S (editors): Cochrane Handbook for Systematic Reviews of Interventions Version 5.0. The Cochrane Collaboration, Available from www.cochrane-handbook. org. Accessed February 1, 2008.
8. Avikainen V, von Bonsdorff H, Partio E, et al. Low molecular weight heparin (enoxaparin) compared with unfractionated heparin in prophylaxis of deep venous thrombosis and pulmonary embolism in patients undergoing hip replacement. Ann Chir Gynaecol 1995;84:85-90.
9. Barre J, Pfister G, Potron G, et al. [Comparison of the efficacy and tolerance of Kabi 2165 and standard heparin in the prevention of deep venous thrombosis in total hip prosthesis]. J Mal Vasc 1987;12:90-95.
10. Colwell CW Jr, Spiro TE, Trowbridge AA, et al. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am 1994;76:3-14.
11. Colwell CW Jr, Spiro TE, Trowbridge AA, et al. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep venous thrombosis after elective knee arthroplasty. Enoxaparin Clinical Trial Group. Clin Orthop 1995;321:19-27.
12. Dechavanne M, Ville D, Berruyer M, et al. Randomized trial of a low-molecular-weight heparin (Kabi 2165) versus adjusted-dose subcutaneous standard heparin in the prophylaxis of deep-vein thrombosis after elective hip surgery. Haemostasis 1989;19:5-12.
13. Eriksson BI, Kalebo P, Anthymyr BA, et al. Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. Comparison of low-molecular-weight heparin and unfractionated heparin. J Bone Joint Surg Am 1991;73:484-493.
14. Fauno P, Suomalainen O, Rehnberg V, et al. Prophylaxis for the prevention of venous thromboembolism after total knee arthroplasty. A comparison between unfractionated and lowmolecular- weight heparin. J Bone Joint Surg Am 1994;76:1814-1818.
15. Levine MN, Hirsh J, Gent M, et al. Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med 1991;114:545-551.
16. Menzin J, Richner R, Huse D, et al. Prevention of deep-vein thrombosis following total hip replacement surgery with enoxaparin versus unfractionated heparin: a pharmacoeconomic evaluation. Ann Pharmacother 1994;28:271-275.
17. Planes A, Vochelle N, Mazas F, et al. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemost 1988;60:407-410.
18. Schwartsmann CR, Cavalieri CR, Drumond SN, et al. Randomized, comparative, open study to assess the efficacy and safety of enoxaparin compared with unfractionated heparin in the prophylaxis of venous thromboembolism in patients undergoing total hip arthroplasty. Rev Bras Ortop 1996;31:797-808.
19. Senaran H, Acaroglu E, Ozdemir HM, et al. Enoxaparin and heparin comparison of deep vein thrombosis prophylaxis in total hip replacement patients. Arch Orthop Trauma Surg 2006;126:1-5.
20. Rader CP, Kramer C, König A, et al. Low-molecular-weight heparin and partial thromboplastin time-adjusted unfractionated heparin in thromboprophylaxis after total knee and total hip arthroplasty. J Arthroplasty 1998;13:180-185 PMID: 9526211
21. Monreal M, Lafoz E, Navarro A, et al. A prospective double-blind trial of a low molecular weight heparin once daily compared with conventional low-dose heparin three times daily to prevent pulmonary embolism and venous thrombosis in patients with hip fracture. J Trauma 1989;29:873-5.
22. Bonneux IM, Bellemans J, Fabry G. Evaluation of wound healing after total knee arthroplasty in a randomized prospective trial comparing fondaparinux with enoxaparin. Knee 2006;13:118-121.
23. Eriksson BI, Bauer KA, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thrombo-embolism after hip-fracture surgery. N Engl J Med 2001;345:1298-1304.
24. Lassen M, Bauer K, Eriksson B, et al. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002;359:1715-1720.
25. Turpie AG, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002;359:1721-1726.
26. Bauer KA, Eriksson BI, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001;345:1305-1310.
27. Yokote R, Matsubara M, Hirasawa N, Hagio S, Ishii K, Takata C. Is routine chemical thromboprophylaxis after total hip replacement really neccessary in a Japanese population? J Bone Joint Surg Br 2011;93-B:251-256.
28. Eriksson BI, Borris LC, Dahl OE, et al. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 2006;114(22):2374-2381.
29. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358:2765-2775.
30. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776-2786.
31. Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty: a randomisez trial. Lancet 2009;373:1673-1680.
32. Eriksson BI, Dahl OE, Buller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005;3:103-111.
33. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5:2178-2185.
34. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007;370:949-956.
35. Eriksson BI, Wille-Jorgensen P, Kalebo P, et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997;337:1329-1335.
36. RE-MOBILIZE Writing Committee, Ginsberg JS, Davidson BL, Comp PC, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009;24:1-9.
37. Eriksson BI, Dahl OE, Huo MH, et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II.*). A randomised, double-blind, non-inferiority trial. Thromb Haemost 2011;105(4):721-729.
38. Colwell CW Jr, Collis DK, Paulson R, et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge. J Bone Joint Surg Am 1999;81:932-940.
39. Fitzgerald RH JrSpiro TE, Trowbridge AA, et al. Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel- group comparison of enoxaparin and warfarin. J Bone Joint Surg Am 2001;83-A:900-906.
40. Francis CW, Pellegrini VD Jr, Totterman S, et al. Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin. J Bone Joint Surg Am 1997;79:1365-1372.
41. Hull R, Raskob G, Pineo G, et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 1993;329:1370-1376.
42. Hull RD, Pineo GF, Francis C, et al. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients a double-blind, randomized comparisons. Arch Intern Med 2000;160:2199-207.
43. Lassen MR, Davidson BL, Gallus A, et al. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007;5:2368-2375.
44. Leclerc JR, Geerts WH, Desjardins L, et al. Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin. Ann Intern Med 1996;124:619-26.
45. White CM. Thrombin-directed inhibitors: pharmacology and clinical use. Am Heart J 2005;1(suppl):S54-S60.